Abstract:Since most dominant human mutations are single nucleotide substitutions<a href="/articles/s41591-019-0500-9#ref-CR1">1</a>,<a href="/articles/s41591-019-0500-9#ref-CR2">2</a>, we explored gene editing strategies to disrupt dominant mutations efficiently and selectively without affecting wild-type alleles. However, single nucleotide discrimination can be difficult to achieve<a href="/articles/s41591-019-0500-9#ref-CR3">3</a> because commonly used endonucleases, such as Streptococcus pyogenes Cas9 (SpCas9), can tolerate up to seven mismatches between guide RNA (gRNA) and target DNA. Furthermore, the protospacer-adjacent motif (PAM) in some Cas9 enzymes can tolerate mismatches with the target DNA<a href="/articles/s41591-019-0500-9#ref-CR3">3</a>,<a href="/articles/s41591-019-0500-9#ref-CR4">4</a>. To circumvent these limitations, we screened 14 Cas9/gRNA combinations for specific and efficient disruption of a nucleotide substitution that causes the dominant progressive hearing loss, DFNA36. As a model for DFNA36, we used Beethoven mice<a href="/articles/s41591-019-0500-9#ref-CR5">5</a>, which harbor a point mutation in Tmc1, a gene required for hearing that encodes a pore-forming subunit of mechanosensory transduction channels in inner-ear hair cells<a href="/articles/s41591-019-0500-9#ref-CR6">6</a>. We identified a PAM variant of Staphylococcus aureus Cas9 (SaCas9-KKH) that selectively and efficiently disrupted the mutant allele, but not the wild-type Tmc1/TMC1 allele, in Beethoven mice and in a DFNA36 human cell line. Adeno-associated virus (AAV)-mediated SaCas9-KKH delivery prevented deafness in Beethoven mice up to one year post injection. Analysis of current ClinVar entries revealed that ~21% of dominant human mutations could be targeted using a similar approach.

RNA base editing therapy cures hearing loss induced by OTOF gene mutation.

A base editor for the long-term restoration of auditory function in mice with recessive profound deafness

Hearing of Otof-deficient Mice Restored by Trans-Splicing of N- and C-terminal Otoferlin.

Rescue of autosomal dominant hearing loss by in vivo delivery of mini dCas13X-derived RNA base editor

AAV-Mediated Gene Therapy Restores Hearing in Patients with DFNB9 Deafness

Genetic Correction of TRMU Allele Restored the Mitochondrial Dysfunction-Induced Deficiencies in Ipscs-Derived Hair Cells of Hearing-Impaired Patients.

In vivo outer hair cell gene editing ameliorates progressive hearing loss in dominant-negative Kcnq4 murine model

Treatment of monogenic and digenic dominant genetic hearing loss by CRISPR-Cas9 ribonucleoprotein delivery in vivo

Preclinical Efficacy And Safety Evaluation of AAV‐OTOF in DFNB9 Mouse Model And Nonhuman Primate

Overloaded Adeno-Associated Virus as a Novel Gene Therapeutic Tool for Otoferlin-Related Deafness

PAM-flexible Adenine Base Editing Rescues Hearing Loss in a Humanized MPZL2 Mouse Model Harboring an East Asian Founder Mutation

Hair Cell-specific Myo15 Promoter-mediated Gene Therapy Rescues Hearing in DFNB9 Mouse Model

Gene editing in a Myo6 semi-dominant mouse model rescues auditory function

[Study on Gene Therapy for DPOAE and ABR Threshold Changes in Adult Otof-/- Mice].

Precise Detection of CRISPR-Cas9 Editing in Hair Cells in the Treatment of Autosomal Dominant Hearing Loss

Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss

Preventing autosomal-dominant hearing loss in Bth mice with CRISPR/CasRx-based RNA editing

Preclinical evaluation of the efficacy and safety of AAV1-hOTOF in mice and nonhuman primates

AAV-ie-K558R mediated cochlear gene therapy and hair cell regeneration

Prevention of acquired sensorineural hearing loss in mice by in vivo Htra2 gene editing

Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents